Drugs / CnU
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07005752 | Jul 2025 → Jun 2026 overdue | cholelithiasis | Myungmoon Pharma. Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CnU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07005752 ↗ |
| Known as | CnU capsule | “CnU capsule(Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid) and Ursa placebo tablet will be orally administered three times a day after meals at...” NCT07005752 ↗ |